Dr. Lisa A. Kachnic

Lisa A. Kachnic, MD, one of the nation’s leading radiation oncologists and a pioneer of new approaches to optimize the effectiveness of radiation therapy, is the Chu H. Chang Professor and Chief of the Department of Radiation Oncology at Columbia University Vagelos College of Physicians and Surgeons (VP&S) and Chief of the Radiation Oncology Service at NewYork-Presbyterian/Columbia University Irving Medical Center (CUIMC). She also serves as Associate Director of Radiation Oncology and Science in the Herbert Irving Comprehensive Cancer Center (HICCC). Dr. Kachnic’s combined focus on clinical excellence, technological innovation, and patient-centered research continues to advance the field of radiation oncology, which has resulted in over 150 publications and over $17 million in research support from major federal and non-profit agencies. She is widely recognized for gastrointestinal research that has transformed the standard of care for several cancers by integrating novel radiation delivery techniques. A past president of the American Board of Radiology, Dr. Kachnic is internationally known for her clinical trial leadership positions in the National Cancer Institute and its cooperative group research bases. She currently serves as Vice Chair of the Radiation Oncology Committee and Co-Chair of the Ano-Rectal Subcommittee for the SWOG Cancer Research Network research base, for which she is the multi-modality executive officer, as well as NRG Oncology’s Associate PI of their NCORP (NCI Community Oncology Research Program) and chair of the NCORP’s Cancer Control Committee. At Columbia, she is contact PI of Columbia’s NCORP and is co-PI of several NCI training grants for residents and early career faculty.

Dr. Kachnic is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Anal Cancer, Anaplastic Large Cell Lymphoma, Esophageal Cancer, and T-Cell Lymphoma.

Dr. Kachnic is board certified in Radiation Oncology. She is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 5 clinical trials. Dr. Kachnic is currently accepting new patients.